Cargando…
HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
The HDL hypothesis stating that simply raising HDL cholesterol (HDL-C) may produce cardiovascular benefits has been questioned recently based on several randomized clinical trials using CETP inhibitors or niacin to raise HDL-C levels. However, extensive pre-clinical data support the vascular protect...
Autores principales: | Chyu, Kuang-Yuh, Shah, Prediman K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555973/ https://www.ncbi.nlm.nih.gov/pubmed/26388776 http://dx.doi.org/10.3389/fphar.2015.00187 |
Ejemplares similares
-
Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018) -
HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013) -
Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015) -
Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007) -
Serum Levels of ApoA1 and ApoA2 Are Associated with Cognitive Status in Older Men
por: Ma, Cheng, et al.
Publicado: (2015)